While there had been some doubt if Isis (NASDAQ:IONS) and its partner Sanofi (NYSE:SNY) would have their inherited cholesterol disorder drug Kynamro approved, news today that it received FDA approval shot Isis shares up 10%, while competitor Aegerion (NASDAQ:AEGR) was down 2% on the news. In this video, Motley Fool health-care analyst David Williamson tells us some of the headwinds and tailwinds investors can expect for the drug, and how well he sees it competing with Aegerion's Juxtapid in the same space.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.